Palisade Bio (PALI) Return on Capital Employed (2011 - 2026)
Palisade Bio (PALI) reported Return on Capital Employed of 20.66% for Q1 2026, up 17904.0% year-over-year from N/an in Q1 2025, and up 24.44% on a QoQ basis from 27.35% in Q4 2025.
Palisade Bio (PALI) has 16 years of Return on Capital Employed data on file, last reported at 20.66% in Q1 2026.
- Quarterly Return on Capital Employed rose 17904.0% year-over-year to 20.66% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.66% (up 17904.0% YoY) and the FY2025 annual result came in at 26.56%, up 13442.0% from the prior year.
- Return on Capital Employed advanced to 20.66% in Q1 2026 per PALI's latest filing, from 27.35% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 20.66% in Q1 2026 and bottomed at 511.14% in Q1 2022.
- The 5-year median for Return on Capital Employed is 149.27% (2024), against an average of 182.4%.
- The widest annual swing landed in 2022, when Return on Capital Employed slumped 33230 bps; it then jumped 40998 bps in 2023.
- Tracing PALI's Return on Capital Employed over 5 years: stood at 120.91% in 2022, then gained by 17 bps to 100.74% in 2023, then tumbled by 115 bps to 216.23% in 2024, then soared by 87 bps to 27.35% in 2025, then grew by 24 bps to 20.66% in 2026.
- Per Business Quant, the three latest PALI Return on Capital Employed figures stand at 20.66% (Q1 2026), 27.35% (Q4 2025), and 342.82% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | -20.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.66% |
| Dec 31, 2025 | -27.35% |
| Sep 30, 2025 | -342.82% |
| Jun 30, 2025 | -350.67% |
| Mar 31, 2025 | -199.70% |
| Dec 31, 2024 | -216.23% |
| Sep 30, 2024 | -173.71% |
| Jun 30, 2024 | -149.27% |
| Mar 31, 2024 | -130.58% |
| Dec 31, 2023 | -100.74% |
| Sep 30, 2023 | -91.58% |
| Jun 30, 2023 | -99.71% |
| Mar 31, 2023 | -101.16% |
| Dec 31, 2022 | -120.91% |
| Sep 30, 2022 | -186.55% |
| Jun 30, 2022 | -277.94% |
| Mar 31, 2022 | -511.14% |
| Dec 31, 2021 | -351.81% |
| Sep 30, 2021 | -323.63% |
| Jun 30, 2021 | -493.36% |
| Mar 31, 2021 | -178.84% |
| Dec 31, 2020 | -878.46% |
| Sep 30, 2020 | -51.41% |
| Jun 30, 2020 | -59.67% |
| Mar 31, 2020 | -104.88% |
| Dec 31, 2019 | -132.00% |
| Sep 30, 2019 | -178.53% |
| Jun 30, 2019 | -243.56% |
| Mar 31, 2019 | -156.83% |
| Dec 31, 2018 | -124.17% |
| Sep 30, 2018 | -119.62% |
| Jun 30, 2018 | -95.88% |
| Mar 31, 2018 | -99.88% |
| Dec 31, 2017 | -98.41% |
| Sep 30, 2017 | -129.44% |
| Jun 30, 2017 | -138.88% |
| Mar 31, 2017 | -119.31% |
| Dec 31, 2016 | -251.85% |
| Sep 30, 2016 | -640.14% |
| Jun 30, 2016 | -625.68% |
| Mar 31, 2016 | -419.49% |
| Dec 31, 2015 | -164.86% |
| Sep 30, 2015 | -119.40% |
| Jun 30, 2015 | -80.95% |
| Mar 31, 2015 | -64.93% |
| Dec 31, 2014 | -68.02% |
| Sep 30, 2014 | -61.42% |
| Jun 30, 2014 | -51.51% |
| Mar 31, 2014 | -64.40% |
| Dec 31, 2013 | -93.79% |
| Sep 30, 2013 | -110.18% |
| Jun 30, 2013 | -98.61% |
| Mar 31, 2013 | -112.28% |
| Dec 31, 2012 | -123.26% |
| Sep 30, 2012 | -182.34% |
| Jun 30, 2012 | -270.31% |
| Mar 31, 2012 | -377.82% |
| Dec 31, 2011 | -507.22% |
| Sep 30, 2011 | -297.30% |